The biotech sector is one that’s become red-hot, at least in recent years. After around a decade of stagnation, investors ...

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is one of the best future stocks to buy for the long term. On January 12, ...

The company made an even more dramatic claim the following month, when it announced it had created three dire wolves. These ...

1月9日，这家Biotech的股价从高点下跌逼近10%。毫不夸张地形容，这更像是余震，而2025年12月31日当天，它就已经遭遇更猛烈的冲击：收盘价暴跌70%以上，盘后交易跌幅更达到80%。

Nido Biosciences在丹麦、意大利、韩国及英国四国开展试验，共纳入54 名成年患者。据美国联邦临床试验数据库公示信息显示，该试验的主要研究终点为：验证每日一次给药的 NIDO-361，相较于安慰剂，是否能更有效地提升患者大腿肌肉量及整体骨骼肌量，同时试验也对药物安全性进行了评估。

Stock sales from drug developers are off to a flying start on US exchanges in 2026, boosting the prospects for biotechnology ...

英矽智能平台主要就是PHARMA.AI平台，Pharma.AI平台由 Biology42，Chemistry42，Medicine42及Science42组成，旨在整合药物发现及开发过程,以识别新药靶点，针对新品种及已知靶点设计替代分子,优化临床开发,并通过多代理生成式人工智能协助加强研究。此外，该平台由强大的data warehouse ...

Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...

This session examines Saudi Arabia’s value proposition as a regional manufacturing hub for healthcare and medical ...

同样在去年12月，聚焦肿瘤ADC领域的初创公司Mythic终止了唯一的临床试验，其研发设备、IP和平台技术陆续被挂牌出售。而Mythic走向衰败的原因更令人惋惜——虽然产品颇具科学前景，但无法阻挡资本对ADC领域的热情降温，最终公司资金链断裂。

Explore how leadership in biotech drives success through a milestone approach, aligning teams and culture from science to ...

The discussion focuses on how KAIMRC integrates clinical research, biobanking, data infrastructure, and translational science ...